Introduction: Statin-induced myopathy is an important cause of statin intolerance and the
most common cause of statin discontinuation. Observational studies estimate that 10–15 …

OBJECTIVE: Patients with dyslipoproteinemia constitute the largest risk group for
development of atherosclerosis and cardiovascular disease (CVD). Despite extensive statin …

HMG-CoA reductase inhibitors ('statins') represent the most effective and widely prescribed
drugs currently available for the reduction of low-density lipoprotein cholesterol, a critical …

Objective: To systematically review and analyse evidence for cholesterol-lowering efficacy of
at least 4 weeks of add-on ezetimibe vs doubling statin dose, in adults with primary …

The present multicenter, 6-week, randomized, double-blind, parallel-group, clinical trial
evaluated the safety and efficacy of ezetimibe (10 mg) added to stable rosuvastatin therapy …

Objectives To evaluate the lipid-altering efficacy and safety of ezetimibe monotherapy in
young children with heterozygous familial hypercholesterolemia (HeFH) or nonfamilial …

This review focuses on the non-statin strategies for the treatment of hyperlipidemias in
humans. Even if statins remain the major hypolipidemic drugs at present, an increasing …

Aim: This post hoc analysis compared the lipid‐altering efficacy and safety of ezetimibe 10
mg plus statin (EZE/statin) vs. statin monotherapy in hypercholesterolaemic patients with …

Background: Statin therapy effectively prevents vascular disease, but treatment targets are
often not achieved. Purpose: To compare the benefits and harms of high-dose statin …

The aim of this study was to evaluate the efficacy and safety of ezetimibe 10 mg added to
atorvastatin 20 mg compared with doubling atorvastatin to 40 mg in patients with …